{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:03:40Z","timestamp":1770077020312,"version":"3.49.0"},"reference-count":65,"publisher":"Informa UK Limited","issue":"7","funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2016,7,2]]},"DOI":"10.3111\/13696998.2016.1164174","type":"journal-article","created":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T07:41:50Z","timestamp":1460706110000},"page":"718-727","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada"],"prefix":"10.3111","volume":"19","author":[{"given":"Wenqing","family":"Su","sequence":"first","affiliation":[{"name":"Evidera, Bethesda, MD, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuraag","family":"Kansal","sequence":"additional","affiliation":[{"name":"Evidera, Bethesda, MD, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Vicente","sequence":"additional","affiliation":[{"name":"PIVINA Consulting, Inc., Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baris","family":"Deniz","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujata","family":"Sarda","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,4,15]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1564682"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.11.010"},{"key":"CIT0003","unstructured":"World Health Organization. Atlas of multiple sclerosis resources in the world. Geneva, Switzerland: World Health Organization, 2008. http:\/\/www.who.int\/mental_health\/neurology\/Atlas_MS_WEB.pdf. Accessed September 16, 2013"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.58276"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1177\/1352458507084264"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2009.08.003"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509107007"},{"issue":"14","key":"CIT0008","first-page":"P7","volume":"84","author":"Bar-Or A","year":"2015","journal-title":"Neurol"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"CIT0010","unstructured":"Multiple Sclerosis Trust. A to Z of MS: Expanded Disability Status Scale (EDSS). 29 October 2013. Letchworth Garden City, UK: Multiple Sclerosis Trust, 2013. http:\/\/www.mstrust.org.uk\/atoz\/edss.jsp. Accessed November 2013"},{"key":"CIT0011","first-page":"175","volume":"37","author":"Goldenberg MM","year":"2012","journal-title":"Pharm Therapeut"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.4.655"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390304"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.7.1268"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03334-0"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1206328"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114287"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826070-00008"},{"key":"CIT0019","unstructured":"Multiple Sclerosis Society of Canada, Disease-modifying therapies, Toronto, Canada: Multiple Sclerosis Society of Canada, 2016. https:\/\/mssociety.ca\/about-ms\/treatments\/disease-modifying-therapies-dmts. Accessed March 30, 2016"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/122.4.625"},{"key":"CIT0021","doi-asserted-by":"crossref","unstructured":"Dorman E, Kansal AR, Sarda S, The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada, 2015;18:1085-91","DOI":"10.3111\/13696998.2015.1076826"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh721"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/112.6.1419"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1970.tb05808.x"},{"key":"CIT0025","unstructured":"NICE. Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis.NICE technology appraisal 254 (TA254). London: National Institute for Health and Care Excellence (NICE), 2012. http:\/\/www.nice.org.uk\/guidance\/TA254. Accessed October 11, 2013"},{"key":"CIT0026","unstructured":"NICE. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis (manufacturer submission to NICE). NICE technology appraisal 127 (TA127). London: National Institute for Health and Care Excellence (NICE), 2007. http:\/\/www.nice.org.uk\/TA127. Accessed October 11, 2013"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A1659"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh104"},{"key":"CIT0029","first-page":"101","volume":"29","author":"Pokorski RJ","year":"1997","journal-title":"J Insur Med"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.5.991"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1191\/1352458502ms811oa"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1177\/135245850000600207"},{"key":"CIT0033","first-page":"e11","volume":"19","author":"Karampampa K","year":"2012","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"CIT0034","unstructured":"NICE. Teriflunomide for treating relapsing-remitting multiple sclerosis. NICE technology appraisal 303 (TA303). London: National Institute for Health and Care Excellence (NICE), 2014. http:\/\/www.nice.org.uk\/guidance\/ta303. Accessed March, 2014"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100053804"},{"key":"CIT0036","unstructured":"Ontario Ministry of Health and Long-term Care. Ontario Health Insurance (OHIP) Schedule of Benefits and Fees. Ontario, Canada: Ontario Ministry of Health and Long-term Care, 2013. http:\/\/www.health.gov.on.ca\/english\/providers\/program\/ohip\/sob\/sob_mn.html. Accessed December 3, 2013"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.3310\/hta10010"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7388.522"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2002.51052.x"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2004.75007.x"},{"key":"CIT0041","first-page":"159","volume":"27","author":"Rubio-Terres C","year":"2003","journal-title":"Farm Hosp"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.890936"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1017\/S026646230010203X"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.68.2.144"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00485.x"},{"key":"CIT0046","unstructured":"Rudick R, Kappos L, Polman C, et al. Long-term outcomes in natalizumab-treated patients who were free of disease activity over the 2-year affirm study. Amsterdam: 5th Joint Triennial Congress of The European and Americas Committees for Treatment and Research in Multiple Sclerosis (ACTRIMS \/ECTRIMS), 2011; Abstract no.:P513"},{"key":"CIT0047","doi-asserted-by":"crossref","unstructured":"Arnason B, Connor P, Knappertz K, et al. Depression incidence and course in multiple sclerosis patients treated with interferon beta-1b and glatiramer acetate during the BEYOND trial. J Neurol Sci 2009;285:S211","DOI":"10.1016\/S0022-510X(09)70805-6"},{"key":"CIT0048","doi-asserted-by":"crossref","unstructured":"Bornstein MB, Miller A, Slagle S, et al. A pilot trial of cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408-14","DOI":"10.1056\/NEJM198708133170703"},{"key":"CIT0049","unstructured":"Fox R, Miller D, Phillips T, et al. Baseline characteristics of patients enrolled in a randomized, multicenter, placebo-controlled and active comparator trial evaluating efficacy and safety of BG-12 in relapsing-remitting multiple sclerosis: the CONFIRM trial. Ontario, Canada: American Academy of Neurology (AAN) 62nd Annual Meeting, 2010; Abstract no.:P06"},{"key":"CIT0050","doi-asserted-by":"crossref","unstructured":"Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: Results of a phase III multicenter, double- blind, placebo-controlled trial. Neurology 1995;45:1268-76","DOI":"10.1212\/WNL.45.7.1268"},{"key":"CIT0051","unstructured":"Gold R, Kappos L, Bar-Or A, et al. Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial. Amsterdam:5th Joint Triennial Congress of The European and Americas Committees for Treatment and Research in Multiple Sclerosis (ACTRIMS \/ECTRIMS), 2011; Abstract no.:95"},{"key":"CIT0052","unstructured":"Von Rosenstiel P, Hohlfeld R, Calabresi P, et al. Clinical outcomes in subgroups of patients treated with fingolimod (FTY720) or placebo: 24-month results from FREEDOMS. Mult Scler 2010;16: S143"},{"key":"CIT0053","doi-asserted-by":"crossref","unstructured":"PRISM study group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-1504","DOI":"10.1016\/S0140-6736(98)03334-0"},{"key":"CIT0054","doi-asserted-by":"crossref","unstructured":"Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFN(beta)2-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72: 1976-83","DOI":"10.1212\/01.wnl.0000345970.73354.17"},{"key":"CIT0055","doi-asserted-by":"crossref","unstructured":"Calabrese M, Bernardi V, Atzori M, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler 2011;18:418-24","DOI":"10.1177\/1352458510394702"},{"key":"CIT0056","doi-asserted-by":"crossref","unstructured":"Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand 2006;113:283-7","DOI":"10.1111\/j.1600-0404.2006.00585.x"},{"key":"CIT0057","doi-asserted-by":"crossref","unstructured":"Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone): Comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler 2003;9:585-91","DOI":"10.1191\/1352458503ms961oa"},{"key":"CIT0058","doi-asserted-by":"crossref","unstructured":"Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239:67-74","DOI":"10.1016\/j.jns.2005.08.003"},{"key":"CIT0059","doi-asserted-by":"crossref","unstructured":"Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS\/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-7","DOI":"10.1212\/WNL.43.4.662"},{"key":"CIT0060","doi-asserted-by":"crossref","unstructured":"De Stefano N, Sormani MP, Stubinski B, et al. Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study. J Neurol Sci 2011; doi","DOI":"10.1016\/j.jns.2011.08.013"},{"key":"CIT0061","doi-asserted-by":"crossref","unstructured":"Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60","DOI":"10.1016\/S0140-6736(02)08430-1"},{"key":"CIT0062","doi-asserted-by":"crossref","unstructured":"Knobler RL, Greenstein JI, Johnson KP, et al. Systemic recombinant human interferon-(beta) treatment of relapsing-remitting multiple sclerosis: Pilot study analysis and six-year follow-up. J Interferon Res 1993;13:333-40","DOI":"10.1089\/jir.1993.13.333"},{"key":"CIT0063","doi-asserted-by":"crossref","unstructured":"Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon (beta)-1a. Neurology 2000;55:185-92","DOI":"10.1212\/WNL.55.2.185"},{"key":"CIT0064","doi-asserted-by":"crossref","unstructured":"Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14","DOI":"10.1016\/S1474-4422(08)70200-X"},{"key":"CIT0065","unstructured":"Khatri B, Barkhof F, Comi G, et al. Oral fingolimod (FTY720) reduces the rate of relapses that require steroid intervention or hospitalization compared with intramuscular interferon-1a: results from a phase III study (TRANSFORMS) in multiple sclerosis. Ontario, Canada: American Academy of Neurology (AAN) 62nd Annual Meeting, 2010; Abstract no.:P06"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3111\/13696998.2016.1164174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T21:22:50Z","timestamp":1598736170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3111\/13696998.2016.1164174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,15]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7,2]]}},"alternative-id":["10.3111\/13696998.2016.1164174"],"URL":"https:\/\/doi.org\/10.3111\/13696998.2016.1164174","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}